{"result": "(\"entity\"<|>HIPONATREMIA<|>EVENT<|>Hiponatremia is a medical condition characterized by low sodium levels in the blood, often requiring treatment adjustments based on volume status.)\n##\n(\"entity\"<|>SISTEMA RENINA ANGIOTENSINA ALDOSTERONA<|>ORGANIZATION<|>The Sistema Renina Angiotensina Aldosterona (SRAA) is a hormone system that regulates blood pressure and fluid balance.)\n##\n(\"entity\"<|>ASCITIS<|>EVENT<|>Ascitis is the accumulation of fluid in the abdominal cavity, often associated with liver disease and requiring specific management strategies.)\n##\n(\"entity\"<|>DIURÉTICOS<|>ORGANIZATION<|>Diuréticos are medications that promote the excretion of water and salts from the body, commonly used in the treatment of hypertension and fluid retention.)\n##\n(\"entity\"<|>ALBUMINA<|>ORGANIZATION<|>Albúmina is a protein in blood plasma that helps maintain oncotic pressure and is used in the treatment of conditions like ascites.)\n##\n(\"relationship\"<|>HIPONATREMIA<|>SIADH<|>Hiponatremia is a common consequence of SIADH, requiring careful management<|>8)\n##\n(\"relationship\"<|>ASCITIS<|>HIPONATREMIA<|>Ascitis can lead to hyponatremia due to fluid imbalance and requires specific treatment approaches<|>6)\n##\n(\"relationship\"<|>SISTEMA RENINA ANGIOTENSINA ALDOSTERONA<|>HIPONATREMIA<|>The Sistema Renina Angiotensina Aldosterona plays a role in the regulation of sodium levels, impacting hyponatremia management<|>7)\n##\n(\"relationship\"<|>DIURÉTICOS<|>HIPONATREMIA<|>Diuréticos can contribute to the development of hyponatremia, especially if not managed properly<|>5)\n##\n(\"relationship\"<|>ALBUMINA<|>ASCITIS<|>Albúmina is often administered to patients with ascites to help manage fluid balance<|>7)\n<|COMPLETE|>", "input": "MANY entities and relationships were missed in the last extraction. Remember to ONLY emit entities that match any of the previously extracted types. Add them below using the same format:\n", "parameters": {"model": "gpt-4o-mini", "temperature": 0.0, "frequency_penalty": 0.0, "presence_penalty": 0.0, "top_p": 1.0, "max_tokens": 4000, "n": 1}, "history": [{"role": "user", "content": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: .\nTV: tolvaptán, NaS: natremia sérica, SG: suero glucosado, DDAVP: desmopresina.\nAdaptado del algoritmo multidisplinar español de manejo del SIADH. Nefrología, 2014.\n\n| REPONER LA VOLEMIA |\n|---------------------|\n| HipoNa<br>HIPO-volémica | Nutrición enteral (NE)<br>SFS al 0,9% iv | Nutrición parenteral (NP)<br>Opción A: SFS al 0,9% iv<br>Opción B: ↑ Na y volumen de NP |\n| | Además, en caso de: Diuréticos (retirar), ISP 1ª (hidrocortisona),<br>Déficit aislado de aldosterona (fludrocortisona) |\n\n| DISMINUIR EL APORTE DE LÍQUIDOS + Na (mínimo 136 mEq/día) |\n|-----------------------------------------------------------|\n| HipoNa<br>EU-volémica | NE : Fórmula hipercalórica | NP : Concentrar la fórmula y la medicación iv |\n| | ↑↑ fisiológica ADH<br>Dolor (analgesia)<br>Náusea (antihemético) | SIADH<br>OsmU > 350: Furosemida (F)<br>No respuesta a F: Tolvaptán (si es posible) | ISP 2ª (déficit<br>de ACTH)<br>Hidrocortisona |\n\n| DISMINUIR EL APORTE DE LÍQUIDOS + Na (mínimo 136 mEq/día) |\n|-----------------------------------------------------------|\n| HipoNa<br>HIPER-volémica | FUROSEMIDA |\n| | OTROS: Bloqueo SRAA, paracentesis y albúmina (ascitis) |\n| | NE: Fórmula hipercalórica | NP: Concentrar la fórmula y la medicación iv |\n\nFigura 5. Tratamiento de la hiponatremia no grave ajustado al tipo y etiología de la\nmisma, durante la administración de la nutrición artificial. SFS: suero fisiológico\nsalino; ISP: insuficiencia suprarrenal primaria; Na: sodio; SRRA: sistema renina\nangiotensina aldosterona.\n\nria, insuficiencia cardiaca aguda y cirrosis con ascitis.\n\n4) Tratamiento ajustado al tipo y etiología de la HipoNa:\n\n   • Hipovolémica. Reponer la volemia con solución\n     salina isotónica. Además de retirar el diurético,\n     administrar hidrocortisona en la insuficiencia\n\nsuprarrenal primaria y fludrocortisona en algunos casos de hipoaldosteronismo aislado.\n\n• Hipervolémica. Disminuir el aporte de líquidos\n  (fórmula hipercalórica en NE, concentrar la medicación intravenosa y la fórmula de NP), administrar furosemida y un aporte mínimo de sodio de\n  136 mEq/día para garantizar su acción terapéuti-\n---\n814      BLOQUE: SOPORTE NUTRICIONAL AVANZADO\n\nca. Valorar otras terapias: bloqueo del SRAA y en pacientes con ascitis (paracentesis y albúmina).\n- Euvolémica. Disminución de los líquidos e incremento del aporte de sodio, al igual que en la HipoNa hipervolémica. En la elevación de la ADH por dolor y náusea, administrar antieméticos y analgesia. Así como hidrocortisona en los pacientes con insuficiencia suprarrenal secundaria y furosemida en los pacientes con SIADH y osmolalidad urinaria > 350 mOsmol/kg. En los pacientes con SIADH, si a pesar de las medidas previas persiste la hiponatremia, valorar el uso de tolvaptán; en NE por SNG y en NP por vía oral (deglución y segunda porción del duodeno conservadas). Administrarlo según el protocolo adaptado del algoritmo multidisciplinar y la perfusión conjunta de suero glucosado.\n\n## 7. Bibliografía\n\n1. Hoorn EJ, J L, Zietse R. Development of severe hyponatremia in hospitalized patients: treatment-related risk factors and inadequate management. Nephrol Dial Transplant. 2006; 21:70-6.\n2. Hawkins RC. Age and gender as risk factors for hyponatremia and hypernatremia. Clin Chim Acta. 2003; 337:169-72.\n3. Waikar SS, Mount DB, Curhan GC. Mortality after hospitalization with mild,moderate, and severe hyponatremia. Am J Med. 2009; 122:857-65.\n4. Verbalis JG. Disorders of body water homeostasis. Best Pract Res Clin Endocrinol Metab. 2003 Dec; 17(4):471-503.\n5. Hoorn EJ, Zietse R. Hy\n######################\nOutput:"}, {"role": "assistant", "content": "(\"entity\"<|>TOLVAPTÁN<|>ORGANIZATION<|>Tolvaptán is a medication used in the treatment of hyponatremia, particularly in patients with conditions like SIADH.)\n##\n(\"entity\"<|>SIADH<|>EVENT<|>Syndrome of Inappropriate Antidiuretic Hormone secretion, a condition that can lead to hyponatremia.)\n##\n(\"entity\"<|>NEFROLOGÍA<|>ORGANIZATION<|>Nefrología is a medical journal that published guidelines for managing SIADH in 2014.)\n##\n(\"entity\"<|>FLUDROCORTISONA<|>ORGANIZATION<|>Fludrocortisona is a medication used to treat conditions related to aldosterone deficiency.)\n##\n(\"entity\"<|>HIDROCORTISONA<|>ORGANIZATION<|>Hidrocortisona is a corticosteroid used in the treatment of adrenal insufficiency.)\n##\n(\"entity\"<|>FURSEMIDA<|>ORGANIZATION<|>Furosemida is a diuretic used to treat fluid retention and high blood pressure.)\n##\n(\"entity\"<|>SUERO GLUCOSADO<|>ORGANIZATION<|>Suero glucosado is a glucose solution used in intravenous therapy.)\n##\n(\"entity\"<|>NUTRICIÓN ENTERAL<|>ORGANIZATION<|>Nutrición enteral refers to the delivery of nutrients directly into the gastrointestinal tract.)\n##\n(\"entity\"<|>NUTRICIÓN PARENTERAL<|>ORGANIZATION<|>Nutrición parenteral is the intravenous administration of nutrients, bypassing the gastrointestinal tract.)\n##\n(\"entity\"<|>BIBLIOGRAFÍA<|>EVENT<|>Bibliography section containing references related to the treatment of hyponatremia.)\n##\n(\"relationship\"<|>TOLVAPTÁN<|>SIADH<|>Tolvaptán is used as a treatment option for patients suffering from SIADH-related hyponatremia<|>8)\n##\n(\"relationship\"<|>HIDROCORTISONA<|>SIADH<|>Hidrocortisona is administered in cases of primary adrenal insufficiency related to SIADH<|>6)\n##\n(\"relationship\"<|>FLUDROCORTISONA<|>SIADH<|>Fludrocortisona is used in cases of isolated aldosterone deficiency, which can be related to SIADH<|>6)\n##\n(\"relationship\"<|>FURSEMIDA<|>SIADH<|>Furosemida is used in the management of fluid retention in patients with SIADH<|>7)\n##\n(\"relationship\"<|>NUTRICIÓN ENTERAL<|>SIADH<|>Nutrición enteral is mentioned as a method to manage fluid and sodium intake in patients with SIADH<|>5)\n##\n(\"relationship\"<|>NUTRICIÓN PARENTERAL<|>SIADH<|>Nutrición parenteral is also mentioned as a method to manage fluid and sodium intake in patients with SIADH<|>5)\n##\n(\"relationship\"<|>NEFROLOGÍA<|>SIADH<|>Nefrología published guidelines for the management of SIADH<|>9)\n<|COMPLETE|>"}]}